VRX-0075: Findings from Animal Research

VRX-0075 is an experimental peptide that activates five receptors at once: GLP-1, GIP, glucagon, amylin and calcitonin. At the American Diabetes Association's 86th Scientific Sessions in 2026, researchers reported it produced more weight loss than retatrutide in obese rats at the same molar dose. That result got attention. It is also a late-breaking abstract from an animal study, with no human data behind it.

What the abstract reports

Targets: one long-acting molecule activating GLP-1, GIP, glucagon, amylin and calcitonin receptors
In vitro (lab tests on cells): potency comparable to retatrutide at GLP-1, GIP and glucagon, and comparable to cagrilintide at amylin and calcitonin
Obese rats: significantly greater weight loss than retatrutide at the same molar dose
Half-life: about 50% longer than semaglutide in obese rats, which the authors suggest could support weekly dosing in humans, a hypothesis, not a finding
Safety: no observable toxicology findings, in what the authors describe as a non-regulatory setting, not a formal toxicology program

Source: Douros J, Mowery S, Kalwat M, Dodson S, Shrinivasan R, Knerr PJ. 2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats. Diabetes. 2026;75(Supplement 1):2839-LB.

Where it sits on the receptor ladder

Semaglutide targets GLP-1. Tirzepatide adds GIP. Retatrutide adds glucagon and is in phase 3. VRX-0075 keeps those three and adds amylin and calcitonin signaling, the pathway cagrilintide is built around. See our comparison of semaglutide, tirzepatide and retatrutide for the first three steps.

Why add amylin and calcitonin to a triple agonist?

Amylin is a hormone released with insulin that slows gastric emptying and contributes to satiety. Functional amylin receptors form when the calcitonin receptor pairs with receptor activity-modifying proteins. The design idea is to combine an incretin and glucagon profile with an amylin-type effect in one molecule. Every extra receptor raises a balance problem that a short rat study can't answer.

Does "beat retatrutide in rats" mean it will beat it in people?

No. Rats and humans differ in receptor pharmacology, metabolism and how body weight is regulated, and rodent efficacy often shrinks in the clinic. Retatrutide has human phase 3 data. VRX-0075 has none. The abstract supports further research; it doesn't establish safety, efficacy, dosing or superiority in humans.

Can you buy VRX-0075?

Compound Lab does not stock VRX-0075. The animal findings discussed here do not establish safety or efficacy in humans.

Research use only. Not for human or veterinary use. Not approved by the Thai FDA. Educational content, not medical advice. VRX-0075 is an experimental compound and the findings discussed are preclinical.

Shop Retatrutide → Read the receptor comparison →